FIND A COURSE
The ASAM National Practice Guideline Special Populations Webinar (October)
Includes a Live Event on 10/25/2016 at 3:00 PM (EDT)Adolescents - This webinar will provide important recommendations to help clinicians treat adolescents who have complex medical and environmental needs.
This webinar will be recorded for archived viewing.
This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.
The treatment of adolescents with opioid use disorder presents many unique medical, legal, and ethical dilemmas that may complicate treatment. Given these unique issues, adolescents with opioid use disorder often benefit from services designed specifically for them. The Adolescents Webinar will provide an overview of the recommendation and in-depth information treating adolescents from ASAM's National Practice Guideline.
This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.
At the conclusion of the webinar, participants should be able to:
- Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
- Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
- Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
- Discuss the unique needs and treatment recommendations for adolescents.
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Addiction Medicine (ABAM) MOC:
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.
CME Committee
Name Disclosure Information Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair None Catherine Friedman, MD, Vice Chair, Reviewer
None Noel Ilogu, MD, MRCP None Herbert L. Malinoff, MD, FACP, FASAM None Edwin A. Salsitz, MD, FASAM, Reviewer None John C. Tanner, DO, FASAM, CCFC, MRO Reckitt-Benckiser: Honorarium, Speaker
Orexo: Honorarium, Speaker
BDSI: Honorarium, Speaker & Consultant
Planning Committee
Name Disclosure Information Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None Margaret A. E. Jarvis, MD, FASAM Geisinger Health System: Salary, Medical Director
US Preventive Health: Dividend, Stockholder
Hoffspiegel and Associates: Fees, Expert Witness
Up-to-Date: Royalties, Author
Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director Faculty
Name Disclosure Information Marc Fishman, MD, DFASAM Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property
US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received
Aaron D. Fox, MD, MS None Brian Hurley, MD, MBA, DFASAM None Yngvild Olsen, MD, MPH, FASAM None Tricia Wright, MD, MS, FACOG, FASAM None Marc Fishman
MD, DFASAM
Marc Fishman MD is board certified in addiction psychiatry and addiction medicine. A faculty member of the Johns Hopkins University School of Medicine, he is Medical Director and CEO of Maryland Treatment Centers, a regional behavioral health care provider, with inpatient and outpatient facilities for adolescents and adults. His clinical specialties include treatment of drug-involved and dual-diagnosis adolescents, opioid dependence in adolescents and adults, and co-occurring disorders. He has been principal investigator or collaborator for several NIDA- and CSAT-funded projects to improve and evaluate adolescent treatment, as well as pharmacotherapy trials in adults. He is the author of numerous articles and book chapters on addiction treatment, and lectures widely on a variety of topics including adolescent treatment, youth opioid treatment, placement and treatment matching strategies. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine.
-
Register
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- Non-Member - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
- More Information
Opioid Prescribing: Safe Practice, Changing Lives (2.5 Credits)
Includes a Live Event on 10/05/2016 at 6:30 PM (EDT)Review safe prescribing habits and examine the difference between extended release/long acting medications to help ensure patient safety and effective pain management.
October 5, 2016 | 6:30 pm - 9:00 pm ET
The CO*RE/ASAM Opioid Prescribing: Safe Practice, Changing Lives course addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. ASAM's course also provides an additional unit addressing the common and complex overlap between opioid use and opioid addiction.
Learners will be able to:
- Describe appropriate patient assessment for treatment with ER/LA opioid analgesics, evaluating risks and potential benefits of ER/LA therapy, as well as possible misuse.
- Apply proper methods to initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, applying best practices including accurate dosing and conversion techniques, as well as appropriate discontinuation strategies.
- Demonstrate accurate knowledge about how to manage ongoing therapy with ER/LA opioid analgesics and properly use evidence-based tools while assessing for adverse effects.
- Employ methods to counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal.
- Review/assess general and product-specific drug information concerning ER/LA opioid analgesics and identifying potential adverse effects of ER/LA opioids.
CME Information and Disclosure Listing
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Addiction Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 2.5 AMA PRA Category 1 Credits™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Adam J. Gordon, MD, MPH, FACP, DFASAM
None
Catherine Friedman, MD
None
Noel Ilogu, MD, MRCP None Herbert Malinoff, MD, FACP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
John Tanner, DO, DFASAM
Reckitt
Astra Zeneca
Pfizer
Alkermes
Honorarium
Honorarium
Honorarium
Honorarium
Speaker
Speaker
Speaker
Speaker
Program Planning Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Herbert Malinoff, MD, FACP, DFASAM
None
Yngvild Olsen, MD, MPH
None
Theodore Parran, MD
None
Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, FACEP, DFASAM
None
Course FacultyName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, FACEP, DFASAM None ASAM CME Committee Reviewers
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Jacob Bobrowski, MD, FAAFP
None
Anthony H. Dekker, DO, DFASAM
None
Acknowledgement
Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.
RPC Commercial Support Disclosure Statement
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.
This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.
-
Register
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- Non-Member - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- More Information
The ASAM Buprenorphine Course Webinar
Includes a Live Event on 10/05/2016 at 1:30 PM (EDT)The ASAM Buprenorphine Course will ensure that participants are exposed to the highest quality, evidence-based practices when using buprenorphine to treat opioid use disorders.
Upcoming Webinars:
October 5, 2016 | 1:00 pm - 5:30 pm ETWelcome to the ASAM Buprenorphine Waiver Course online access. To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select Forgot Password and you will be emailed a link to reset your password.
This is an 8 hour blended course combining 4 hours of online learning followed by 4 hours of live webinar learning. The live portion of the course builds off the content delivered in the online portion. Course faculty are expecting you to come to the live webinar with the online portion completed.
Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.
Once you have completed the 4 hour online portion and the 4 hour live webinar portion of the course, return here to claim CME for the course. If you have any questions, please contact education@asam.org.
The Drug Abuse Treatment Act of 2000 (DATA 2000)
DATA 2000 specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses. To qualify for authority to prescribe buprenorphine for the treatment of opioid dependence, DATA 2000 requires physicians to complete not less than 8 hours of training.The ASAM Buprenorphine Waiver Blended Course Format
ASAM offers this 8 hour course in a blended format combining online and live learning to meet the needs of today's busy physicians. The first half of the course is administered online through 4 hours of independent self-paced learning followed by a competency exam which must be successfully completed as part of the process to obtain a waiver for prescribing buprenorphine. The second half of the course is delivered by recognized national experts in a 4 hour interactive and engaging face to face classroom setting.Daniel P. Alford
MD, MPH, FACP, DFASAM
Dr. Daniel P. Alford is an Associate Professor of Medicine, Assistant Dean of CME and Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine. He is a diplomate in Addiction Medicine by the American Board of Addiction Medicine (ABAM).
He is director of the Clinical Addiction Research and Education Unit medical director of the Office-Based Opioid Treatment (OBOT) program and of the Massachusetts Screening, Brief Intervention, Referral to Treatment Training and Technical Assistance (MASBIRT TTA) program and former program director for the Addiction Medicine Fellowship program at Boston Medical Center (BMC). Since 2001 he has served as the course director of the Chief Resident Immersion Training (CRIT) Program in Addiction Medicine: Improving Clinical and Teaching Skills for Generalists funded by NIDA. He is president of the Association for Medical Education and Research in Substance Abuse (AMERSA). In 2011, he was recognized as a Champion of Change by the White House. In 2014 he received the Health Education Award from the American Medical Association.
Edwin A. Salsitz
MD, DFASAM
Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel, Division of Chemical Dependency, since 1983, and is an Assistant Professor of Medicine at the Mount Sinai Icahn School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.
Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings, and is a mentor in the PCSS mentoring program, both for buprenorphine and opioids. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine. Dr. Salsitz is the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. He currently is the chair of the ASAM REMS ER/LA Committee.
Dr. Salsitz is the recipient of the 2014 Annual ASAM Award.
Sarah Bagley
MD
Sarah Bagley, MD, is an attending in the Departments of Medicine and Pediatrics at Boston Medical Center. Sarah completed a Combined Residency in Internal Medicine and Pediatrics at Brown and then an Addiction Medicine Fellowship at Boston University. Her clinical and research interest are related to the impact of substance use on families and in the treatment of adolescents with substance use disorders.
Jeffrey Baxter
MD
Jeff Baxter, MD, is an Associate Professor of Family Medicine and Community Health at the University of Massachusetts Medical School. Dr. Baxter completed a fellowship in Addiction Medicine at the Boston VA Medical Center, and is board certified in Family Medicine and Addiction Medicine. He currently serves as the Chief Medical Officer for Spectrum Health Systems Addiction Treatment Services, overseeing inpatient, outpatient and residential divisions.
Colleen LaBelle
BSN, RN-BC, CARN
Colleen LaBelle has certifications in addiction nursing and HIV with over 20 years of clinical experience in HIV and addiction, and co-authored a publication in the Journal of General Internal Medicine, “Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-based Setting." She was instrumental in the start up of the OBOT Program in the BMC Primary Care Clinic, which manages over 450 active patients with buprenorphine. This program provides buprenorphine treatment for patients in primary care, homeless, HIV, Family Medicine, OB, and support to the affiliated community health centers. She is the program director of the STATE OBOT B (State Technical Assistance, Treatment Expansion of Buprenorphine) working with 14 community health centers implementing a nurse care manager model for the expansion of buprenorphine. Since 2003, Ms. LaBelle has served as Faculty for the buprenorphine certification course of the American Society of Addiction Medicine. She frequently gives presentations on buprenorphine and provides consultation and technical assistance on- and offsite and by telephone. She oversees the MDPH buprenorphine list-serve and provides liaison for MDPH supported buprenorphine training, education and start-up in Massachusetts. She speaks on a local and national level, and has been a part of the SAMHSA Summit on Buprenorphine. Ms. LaBelle has served as a member of the Scientific Study (Study Section) Review Committee for the National Institute on Drug Abuse. Since 2004, she has served on the National Advisory Committee on Buprenorphine for the Health Resources and Services Administration and participated in professional editing of TAP 30 Technical Assistance Publication for Nurses with SAMHSA, 2009. Co-author : Five Year Experience with Collaborative Care of Opioid Addicted Patients using Buprenorphine in Primary Care, published Archives of Internal Medicine. In May 2011 she was the recipient of Individual Leadership Award, for Innovation In Health Care from MA Bureau of Substance Abuse Services as well as a NIATX award recipient 2011 Innovations in Behavioral Health Services award for Process Improvements. She is a board member of the Addiction Nurses Certification Board, and recently started a MA Chapter for addiction nurses.
Sharon Levy
MD, MPH
Sharon Levy, MD, MPH, is a board certified Developmental-Behavioral Pediatrician and an Assistant Professor of Pediatrics at Harvard Medical School; she also has a Master's degree from the Harvard School of Public Health. She is the Director of the Adolescent Substance Abuse Program in the Divi-sion of Developmental Medicine at Boston Children's Hospital where she has evaluated and treated hundreds of adolescents with substance use disorders. She has published extensively on the outpatient management of substance use disorders in adolescents, including screening and brief advice in primary care, the use of drug testing and the outpatient management of opioid de-pendent adolescents. She is the PI of the SAMHSA-funded medical residen-cy SBIRT project at Children's Hospital Boston and an NIAAA-funded study validating the youth alcohol screening tool in a population of youth with chronic medial illness. Dr. Levy currently serves as the chair of the American Academy of Pediatrics Committee on Substance Abuse.
Paula Lum
MD, MPH, FASAM
Dr. Lum is a general internist and primary care physician, and Professor of Medicine in the HIV/AIDS Division in the University of California, San Francisco's Department of Medicine at San Francisco General Hospital. She is certified by the American Boards of Internal Medicine and Addiction Medicine.
Kelley Saia
MD
Kelley Saia, MD, is an attending obstetrician in the Department of Obstetrics and Gynecology at Boston Medical Center and an Assistant Professor of Obstetrics and Gynecology at Boston University School of Medicine.Dr. Saia received her medical degree from the University of Vermont, College of Medicine and completed her residency in obstetrics and gynecology at Boston Medical Center.
In addition to caring for women with general obstetrics and gynecologic issues, she is the director of Project RESPECT, Substance Use Disorder Treatment in pregnancy at Boston Medical Center. Project RESPECT has been caring for pregnant women with substance use disorder for over 30 years and Dr. Saia, established the first obstetric buprenorphine clinic in the greater Boston area in 2006. RESPECT cares for over 125 mother-baby pairs per year with a multidisciplinary team consisting of obstetricians, addiction medicine specialist, pediatrics, psychiatry, social work, lactation consultants and nursing. Dr. Saia is actively engaged in patient care QI, clinical and scientific research, community outreach and medical training.
Andrew Saxon
MD, FASAM
Andrew J. Saxon, M.D. Professor, Department of Psychiatry and Behavioral Sciences, University of Washington Director, Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System Director, Addiction Psychiatry Residency Program, University of Washington Preceding his entry into psychiatry, Dr. Saxon completed an internal medicine internship and worked for 4 years as an emergency room physician. Subsequent to his general psychiatry residency at the University of Washington, Dr. Saxon has more than a quarter century of experience as a clinical and research addiction psychiatrist. Dr. Saxon is board certified with added qualifications in addiction psychiatry by the American Board of Psychiatry and Neurology. Dr. Saxon sits on the editorial boards of the journals, Drug and Alcohol Dependence and General Hospital Psychiatry. Dr. Saxon's current research work is supported by the VA, the Department of Defense, and the National Institute on Drug Abuse and involves pharmacotherapies and psychotherapies for alcohol, cocaine, tobacco, and opioid use disorders as well work in co-occurrence of substance use disorders and posttraumatic stress disorder and on reducing homelessness.
Alexander Y. Walley
MD, MSc, FASAM
Alexander Y. Walley, M.D., M.Sc., is an Assistant Professor of Medicine at Boston University School of Medicine, a general internist and addiction medicine specialist at Boston Medical Center. He does clinical and research-related work on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based buprenorphine treatment for HIV patients at Boston Medical Center and methadone maintenance treatment at Community Substance Abuse Centers. He is the medical director for the Massachusetts Department of Public Health's Opioid Overdose Prevention Pilot Program. He is the Director of the Boston University Addiction Medicine Fellowship program.
Click here for more information on applying for a waiver to prescribe buprenorphine.
The ASAM National Practice Guidelines for the Use of Medications in the Treatment of Addiction Involving Opioid Use: Click here to view ASAM's newly released National Practice Guideline.
Prescribers Clinical Support System for Medication Assisted Treatment - A national training and mentoring project developed in response to the prescription opioid misuse epidemic and the availability of newer pharmacotherapies to address opioid dependence.
- Mentoring for those providing care for opioid dependent individuals available at no cost to all interested providers. Click here.
- Clinical Tools (clinical guidances, sample forms including: patient information, intake forms, treatment agreements, induction forms, TIPs and more). Click here.
SAMHSA Buprenorphine website: Click here to access SAMHSA's website for more information on buprenorphine prescribing. For questions on licensure, DEA-X number etc., please call 866-287-2728 or email info@buprenorphine.samhsa.gov.
DATA Physician Locator: Click here for SAMHSA's physician locator.
Waiver Notification Form: Click here for more information from SAMHSA on how to obtain a waiver and download a waiver notification form.
Agency for Healthcare Research and Quality: Click here for more information from the Agency for Healthcare Research and Quality.
National Institute on Drug Abuse: Click here to visit NIDA's website.
NIDA Buprenorphine Suite of Blending Products: Click here to access NIDA's buprenorphine training for multidisciplinary addiction professionals.
Drug Enforcement Administration: Click here to visit the DEA's website.
A Guide for Law Enforcement on Buprenorphine: Click here to read an article from Huffington Post on Methadone and Buprenorphine.
Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence: Click here for a book by John A. Renner, Jr. and Petros Levounis on treating those with opioid dependence.
How To Fill Out Your NOI Form: Click here for a step-by-step video guide on how to fill out your NOI form. Provided by the American Academy of Addiction Psychiatry.
- Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
- Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
- Continue to Module 1 Part 2 and Module 1 Part 3
- Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
- After you have completed Module 1 Quiz, continue to modules 2 and 3
- You will be required to pass all 3 Module Quizzes with a grade of 70% or higher
- Upon completion of both the 4 online hours and 4 webinar hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center
CME Information and Disclosure Listing
Date of Release: July 2015
Approved Through: July 2018The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The combined online enduring material and live activity will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Adam J. Gordon, MD, MPH, FACP, FASAM, Chair
None
Edwin A. Salsitz, MD, FASAM
None
Herbert Malinoff, MD, FACP, FASAM
None
Noel Ilogu, MD, MRCP
None
Abigail Kay, MD
None
John Tanner, DO, FASAM
Reckitt Benckiser
OREXO
BDSI
Honorarium
Honorarium
Honorarium
Speaker
Speaker
Speaker and Consultant
Catherine Friedman, MD
None
ASAM Buprenorphine Program Planning Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Dan Alford, MD, MPH
None
Andrew J. Saxon, MD
UpToDate
Royalties
Section Editor, Drug Use Disorders
Colleen LaBelle, BSN, RN-BC, CARN
None
Edwin Salsitz, MD, FASAM
None
Jeffrey D. Baxter, MD
None
Kelley Saia, MD
None
Sharon Levy, MD, MPH
None
Paula J. Lum, MD, MPH
None
ASAM Buprenorphine Course FacultyName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Edwin Salsitz, MD, FASAM
None
Andrew J. Saxon, MD
UpToDate
Royalties
Senior Editor, Drug Use Disorders
Colleen LaBelle, BSN, RN-BC, CARN
None
Dan A. Alford, MD, MPH
None
Jeffrey D. Baxter, MD
None
Kelley Saia, MD
None
Sharon Levy, MD, MPH
None
Paula J. Lum, MD, MPH
None
Sarah Bagley, MD
ASAM Millennium Fellowship Award
Partial Salary Support
Awardee
Alexander Y. Walley, MD, MSc
None
ASAM CME Committee Reviewers
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Adam J. Gordon, MD, MPH, FACP, FASAM
None
Herbert Malinoff, MD, FACP, FASAM
None
Learners will be able to:
- Apply for a wavier to prescribe buprenorphine to their patients with opioid use disorders
- Identify and assess patients who are appropriate for treatment with buprenorphine
- Have specific knowledge concerning the use of buprenorphine to manage opioid addicted patients
- Discuss the psychiatric and medical co-morbidities associated with opioid addiction
- Physicians who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.
The ASAM Buprenorphine Course has been made available in part by and unrestricted educational grant from Reckitt Benckiser Pharmaceuticals Inc, a subsidiary of Indivior PLC.
When both the 4 hour online and webinar portions of the course have been completed, CME can be claimed in the e-Learning Center.
-
Register
- Regular Member - $199
- Retired - $199
- Early Career Physician - $199
- Resident - $199
- Student - $199
- Associate - $199
- ASAM Staff - Free!
- Non-Member - $199
- International Member - $199
- Emeritus Member - $199
- Provisional Member - $199
- Fellow Member - $199
- Honorary Member - $199
- More Information
The ASAM National Practice Guideline Special Populations Webinar (August)
Recorded On: 08/30/2016Individuals in the Criminal Justice System - This webinar will provide important recommendations to help clinicians treat individuals in the criminal justice system with opioid use disorder who have complex medical and environmental needs.
This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.
A substantial proportion of persons in prisons, jails, drug courts, probation, parole, and who are criminally involved have opioid use disorder and related problems. Prison drug use is particularly risky because of the environment. The high concentration of at-risk individuals and general overcrowding can increase the risk of adverse consequences associated with drug use, including violence, drug-related deaths, suicide, and self-harm. The Individuals in the Criminal Justice System webinar will provide an overview of the recommendations and in-depth information on treating individuals in the criminal justice system from ASAM's National Practice Guideline.
This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.
At the conclusion of the webinar, participants should be able to:
- Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
- Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
- Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
- Discuss the unique needs and treatment recommendations for individuals in the criminal justice system.
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Addiction Medicine (ABAM) MOC:
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.
CME Committee
Name Disclosure Information Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair None Catherine Friedman, MD, Vice Chair, Reviewer
None Noel Ilogu, MD, MRCP None Herbert L. Malinoff, MD, FACP, FASAM None Edwin A. Salsitz, MD, FASAM, Reviewer None John C. Tanner, DO, FASAM, CCFC, MRO Reckitt-Benckiser: Honorarium, Speaker
Orexo: Honorarium, Speaker
BDSI: Honorarium, Speaker & Consultant
Planning Committee
Name Disclosure Information Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None Margaret A. E. Jarvis, MD, FASAM Geisinger Health System: Salary, Medical Director
US Preventive Health: Dividend, Stockholder
Hoffspiegel and Associates: Fees, Expert Witness
Up-to-Date: Royalties, Author
Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director Faculty
Name Disclosure Information Marc Fishman, MD, DFASAM Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property
US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received
Aaron D. Fox, MD, MS None Brian Hurley, MD, MBA, DFASAM None Yngvild Olsen, MD, MPH, FASAM None Tricia Wright, MD, MS, FACOG, FASAM None -
Register
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- Non-Member - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
- More Information
What Raising the Buprenorphine Cap Means for ASAM Members
Learn about the most recent developments with the new buprenorphine limit, the qualifications needed for prescribing, what a “qualified practice setting” is, and how ASAM members and other doctors may be affected by this recent development.
WHAT: This one-hour webinar provides an overview of the qualifications, requirements and processes related to applying for and maintaining the higher patient limit, as well as specific implications for ASAM members. Importantly, the webinar addresses practice management issues such as documenting a diversion control plan, demonstrating adherence to evidence-based guidelines, and formalizing agreements with behavioral health service providers.
WHO: Physicians interested in applying for the higher limit, as well as their practice managers and care team.
WHY: Evaluate your qualifications for the limit increase and prepare for the application and reporting processes.R. Corey Waller
MD, MS, FACEP, DFASAM
R. Corey Waller, MD, MS, FACEP, DFASAM, is an addiction, pain and emergency medicine specialist. Dr. Waller earned his bachelor's degree in biology and his master's degree in neu-omolecular biology at Southwest Texas State University in San Marcos, Texas. He earned his medical degree at University of Texas Medical School in San Antonio. Dr. Waller completed his emergency medicine residency at Thomas Jefferson University in Philadelphia. He is board certified and fellowship trained in addiction medicine.
Jinhee Lee
Senior Public Health Advisor, Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration
CDR Jinhee Lee, PharmD, is a Senior Public Health Advisor in the Division of Pharmacologic Therapies, Center for Substance Abuse Treatment at the Substance Abuse and Mental Health Services Administration (SAMHSA). She is the co-lead for SAMSHA's Prescription Drug Abuse initiative and the project officer for two SAMHSA PDMP EHR cooperative agreement programs. She has also served as a core member of the Office of the National Coordinator for Health Information Technology's project to improve access to PDMP through Health Information Technology for the last few years.
Prior to joining SAMHSA, CDR Lee was a Senior Regulatory Review Officer at the FDA and also previously worked as a clinical pharmacist at the Washington Hospital Center. She earned her Bachelor of Science degree from the University of California, Los Angeles, Doctor of Pharmacy degree from the University of Illinois, ASHP Pharmacy Practice Residency at the Washington Hospital Center, and an Executive Fellowship in Patient Safety through the Virginia Commonwealth University.
-
Register
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- Non-Member - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- More Information
-
Register
